Skip to main content

Advertisement

SpringerLink
Log in

The Use of Biologic Therapies in Uveitis

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Therapy for autoimmune ophthalmic disease is currently evolving. The improved understanding of the abnormal immune response in the various forms of uveitis has resulted in targeted therapy. The aberrations of the immune system have been characterized by atypical cell populations, cytokine expression, and cell–cell interactions. Different patterns of cytokine expression have now been delineated in the abnormal uveal tract with exaggerated and/or abnormal expression of TNF, IL-1, IL-2, IL-6, and IL-17. The development of therapies for other conditions in which these cytokines play an important role has resulted in the availability of biological agents that have been adopted for use in the therapy for uveitis. Adalimumab and infliximab have been the best studied anti-TNF agents and indeed have now been recommended by an expert panel as first-line treatment of ocular manifestations of Behçet’s disease and second-line treatment for other forms of uveitis (Levy-Clarke et al. (Ophthalmology, 2013). Other anti-TNF agents have been studied as well. Daclizumab, a monoclonal antibody directed against the IL-2 receptor, has also demonstrated utility in treating uveitis as have some of the anti-IL1 agents. Gevokizumab has been granted orphan drug designation for the treatment of resistant forms of uveitis. Therapies affecting IL-6, including tocilizumab are being studied, and available medications that block antigen presenting cell and T cell interaction such as abatacept have been reported to be effective in uveitis. Interferons as well as rituximab have also been evaluated in small studies. Although these biologic therapies have provided a larger armamentarium to treat uveitis, challenges remain. Uveitis is not a single illness; rather, it is a manifestation of many potential systemic diseases that may have very specific individual therapeutic targets. Identifying and characterizing these underlying diseases is not always achieved, and more importantly, the most effective therapies for each entity have not been defined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Levy-Clarke, G., et al., Expert Panel Recommendations for the Use of Anti-Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders. Ophthalmology, 2013.

  2. Ali A, Rosenbaum JT (2010) Use of methotrexate in patients with uveitis. Clin Exp Rheumatol 28(5 Suppl 61):S145–S150

    CAS  PubMed  Google Scholar 

  3. Kaplan-Messas A et al (2003) Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 11(2):131–139

    Article  CAS  PubMed  Google Scholar 

  4. Deuter CM et al (2009) Mycophenolate sodium for immunosuppressive treatment in uveitis. Ocul Immunol Inflamm 17(6):415–419

    Article  CAS  PubMed  Google Scholar 

  5. Klisovic DD (2012) Mycophenolate mofetil use in the treatment of noninfectious uveitis. Dev Ophthalmol 51:57–62

    Article  CAS  PubMed  Google Scholar 

  6. Dick AD, Azim M, Forrester JV (1997) Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol 81(12):1107–1112

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Figueroa MS, Ciancas E, Orte L (2007) Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol 17(1):69–74

    CAS  PubMed  Google Scholar 

  8. Hogan AC et al (2007) Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 114(5):1000–1006

    Article  PubMed  Google Scholar 

  9. Vitale AT, Rodriguez A, Foster CS (1996) Low-dose cyclosporin a therapy in treating chronic, noninfectious uveitis. Ophthalmology 103(3):365–373, discussion 373–4

    Article  CAS  PubMed  Google Scholar 

  10. Kahn P et al (2006) Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 113(5):860–864, e2

    Article  PubMed  Google Scholar 

  11. Mangge H et al (2003) Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int 23(5):258–261

    Article  PubMed  Google Scholar 

  12. Rajaraman RT et al (2006) Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 113(2):308–314

    Article  PubMed  Google Scholar 

  13. Richards JC et al (2005) Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 33(5):461–468

    Article  Google Scholar 

  14. Sharma SM et al (2007) Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis 66(6):840–841

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Simonini G et al (2011) Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 63(4):612–618

    Article  CAS  Google Scholar 

  16. Tynjala P et al (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66(4):548–550

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Zannin ME et al (2013) Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian registry. J Rheumatol 40(1):74–79

    Article  CAS  PubMed  Google Scholar 

  18. Braun J et al (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52(8):2447–2451

    Article  CAS  PubMed  Google Scholar 

  19. Matsuda J et al (2013) Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis. Jpn J Ophthalmol 57(1):104–107

    Article  PubMed  Google Scholar 

  20. Papadia M, Herbort CP (2010) Infliximab-induced demyelination causes visual disturbance mistaken for recurrence of HLA-B27-related uveitis. Ocul Immunol Inflamm 18(6):482–484

    Article  CAS  PubMed  Google Scholar 

  21. Ally MR, Veerappan GR, Koff JM (2008) Treatment of recurrent Crohn’s uveitis with infliximab. Am J Gastroenterol 103(8):2150–2151

    Article  PubMed  Google Scholar 

  22. Fries W et al (2002) Treatment of acute uveitis associated with Crohn’s disease and sacroileitis with infliximab. Am J Gastroenterol 97(2):499–500

    Article  PubMed  Google Scholar 

  23. Benitez-del-Castillo JM et al (2005) Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye (Lond) 19(8):841–845

    Article  CAS  Google Scholar 

  24. Suhler EB et al (2009) Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 127(6):819–822

    CAS  PubMed  Google Scholar 

  25. Suhler EB et al (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123(7):903–912

    Article  CAS  PubMed  Google Scholar 

  26. Kruh JN et al (2014) Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up. Ophthalmology 121(1):358–364

    Article  PubMed  Google Scholar 

  27. Vazquez-Cobian LB, Flynn T, Lehman TJ (2006) Adalimumab therapy for childhood uveitis. J Pediatr 149(4):572–575

    Article  CAS  PubMed  Google Scholar 

  28. Tynjala P et al (2008) Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 47(3):339–344

    Article  CAS  Google Scholar 

  29. Turel Ermertcan, A., et al., Psoriatic uveitis responding to adalimumab therapy. Int J Dermatol, 2013.

  30. Takase K et al (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatol Int 31(2):243–245

    Article  CAS  PubMed  Google Scholar 

  31. Suhler EB et al (2013) Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol 97(4):481–486

    Article  PubMed  Google Scholar 

  32. Soheilian M et al (2012) Bilateral uveitis after phakic intraocular lens implantation and management with adalimumab. J Cataract Refract Surg 38(6):1094–1096

    Article  PubMed  Google Scholar 

  33. Simonini G et al (2013) Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis. Pediatr Rheumatol Online J 11(1):16

    Article  PubMed Central  PubMed  Google Scholar 

  34. Seve P et al (2012) Sarcoid-related uveitis occurring during adalimumab therapy. Ocul Immunol Inflamm 20(1):59–60

    Article  CAS  PubMed  Google Scholar 

  35. Sen ES et al (2012) Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease—a case cohort interventional study. Rheumatology (Oxford) 51(12):2199–2203

    Article  CAS  Google Scholar 

  36. Rudwaleit M et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696–701

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Ramanan AV et al (2014) A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials 15:14

    Article  PubMed Central  PubMed  Google Scholar 

  38. Mushtaq B et al (2007) Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye (Lond) 21(6):824–825

    Article  CAS  Google Scholar 

  39. Martel JN et al (2012) Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm 20(1):18–26

    Article  CAS  PubMed  Google Scholar 

  40. Mansour AM (2007) Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91(3):274–276

    Article  PubMed Central  PubMed  Google Scholar 

  41. Magli A et al (2013) Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 251(6):1601–1606

    Article  CAS  PubMed  Google Scholar 

  42. Li SY, Birnbaum AD, Goldstein DA (2010) Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm 18(6):475–481

    Article  CAS  PubMed  Google Scholar 

  43. Leccese P et al (2011) Efficacy of switching to adalimumab in a patient with refractory uveitis of Behcet’s disease to infliximab. Clin Exp Rheumatol 29(4 Suppl 67):S93

    PubMed  Google Scholar 

  44. Kotaniemi K, Saila H, Kautiainen H (2011) Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 5:1425–1429

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Garcia-De-Vicuna C et al (2013) Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediat Inflamm 2013:560632

    Article  Google Scholar 

  46. Erckens RJ et al (2012) Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 250(5):713–720

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Dobner BC et al (2013) A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol 97(2):134–138

    Article  PubMed  Google Scholar 

  48. Diaz-Llopis M et al (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119(8):1575–1581

    Article  PubMed  Google Scholar 

  49. Diaz-Llopis M et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24(3):351–361

    Article  CAS  PubMed  Google Scholar 

  50. Cordero-Coma M et al (2013) Serum cytokine profile in adalimumab-treated refractory uveitis patients: decreased IL-22 correlates with clinical responses. Ocul Immunol Inflamm 21(3):212–219

    Article  CAS  PubMed  Google Scholar 

  51. Callejas-Rubio JL et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24(6):613–614, author reply 614

    Article  CAS  PubMed  Google Scholar 

  52. Calleja S et al (2012) Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(−) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study. Eye (Lond) 26(3):468–477

    Article  CAS  Google Scholar 

  53. Bravo-Ljubetic L et al (2013) Adalimumab therapy for refractory childhood uveitis. J AAPOS 17(5):456–459

    Article  PubMed  Google Scholar 

  54. Biester S et al (2007) Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91(3):319–324

    Article  PubMed Central  PubMed  Google Scholar 

  55. Androudi S et al (2010) Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 117(8):1612–1616

    Article  PubMed  Google Scholar 

  56. William M et al (2012) Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect 2(4):231–233

    Article  PubMed Central  PubMed  Google Scholar 

  57. Miserocchi, E., et al., Long-term Treatment with Golimumab for Severe Uveitis. Ocul Immunol Inflamm, 2013.

  58. Miserocchi E et al (2013) Golimumab treatment for complicated uveitis. Clin Exp Rheumatol 31(2):320–321

    PubMed  Google Scholar 

  59. Mesquida M et al (2013) Behcet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 21(2):160–162

    Article  CAS  PubMed  Google Scholar 

  60. Faez, S., et al., Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clin Experiment Ophthalmol, 2013.

  61. Cordero-Coma M et al (2011) Golimumab for uveitis. Ophthalmology 118(9):e3–e4, 1892

    Article  PubMed  Google Scholar 

  62. Reiff A et al (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 44(6):1411–1415

    Article  CAS  PubMed  Google Scholar 

  63. Smith BJ, McMillan VM, Newton JS (2001) Corticosteroid-sparing effect of etanercept in idiopathic panuveitis resistant to immunosuppressive therapy. J Clin Rheumatol 7(3):175–178

    Article  CAS  PubMed  Google Scholar 

  64. Foster CS et al (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121(4):437–440

    Article  CAS  PubMed  Google Scholar 

  65. Schmeling H, Horneff G (2005) Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 44(8):1008–1011

    Article  CAS  Google Scholar 

  66. Smith JA et al (2005) A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 53(1):18–23

    Article  CAS  PubMed  Google Scholar 

  67. Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56(10):3248–3252

    Article  CAS  PubMed  Google Scholar 

  68. Sieper J et al (2010) Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 69(1):226–229

    Article  CAS  PubMed  Google Scholar 

  69. Zeboulon N, Dougados M, Gossec L (2008) Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 67(7):955–959

    Article  CAS  PubMed  Google Scholar 

  70. Balshem H et al (2011) GRADE guidelines: 3. rating the quality of evidence. J Clin Epidemiol 64(4):401–406

    Article  PubMed  Google Scholar 

  71. Waldmann TA (2007) Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 27(1):1–18

    Article  CAS  PubMed  Google Scholar 

  72. Nussenblatt RB et al (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 96(13):7462–7466

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Nussenblatt RB et al (2003) Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 21(3):283–293

    Article  CAS  PubMed  Google Scholar 

  74. Yeh S et al (2008) High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun 31(2):91–97

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Nussenblatt RB et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112(5):764–770

    Article  PubMed  Google Scholar 

  76. Wroblewski K et al (2011) Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol 46(4):322–328

    Article  PubMed Central  PubMed  Google Scholar 

  77. Chi W et al (2007) IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 119(5):1218–1224

    Article  CAS  PubMed  Google Scholar 

  78. Dick AD et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120(4):777–787

    Article  PubMed  Google Scholar 

  79. Ooi KG et al (2006) Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype? Clin Med Res 4(4):294–309

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Emmi G et al (2013) Anakinra for resistant Behcet uveitis: why not? Clin Exp Rheumatol 31(3 Suppl 77):152–153

    PubMed  Google Scholar 

  81. Teoh SC et al (2007) Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 91(2):263–264

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. Gul A et al (2012) Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 71(4):563–566

    Article  CAS  PubMed  Google Scholar 

  83. Petrinovic-Doresic J et al (1999) Interleukin 6 and its soluble receptor are elevated in aqueous humor of patients with uveitis. Ocul Immunol Inflamm 7(2):75–84

    Article  CAS  PubMed  Google Scholar 

  84. Muselier A et al (2011) Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 19(5):382–383

    Article  CAS  PubMed  Google Scholar 

  85. Tappeiner C et al (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39(6):1294–1295

    Article  PubMed  Google Scholar 

  86. Adan A et al (2013) Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 251(11):2627–2632

    Article  CAS  PubMed  Google Scholar 

  87. Tsang, A.C., J. Roth, and C. Gottlieb, Tocilizumab for Severe Chronic Anterior Uveitis Associated with Juvenile Idiopathic Arthritis in a Pediatric Patient. Ocul Immunol Inflamm, 2013.

  88. Plskova J, Greiner K, Forrester JV (2007) Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 144(1):55–61

    Article  CAS  PubMed  Google Scholar 

  89. Kenawy N et al (2011) Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 249(2):297–300

    Article  PubMed  Google Scholar 

  90. Miserocchi E, Modorati G (2012) Rituximab for noninfectious uveitis. Dev Ophthalmol 51:98–109

    Article  CAS  PubMed  Google Scholar 

  91. Miserocchi E et al (2011) Rituximab for uveitis. Ophthalmology 118(1):223–224

    Article  PubMed  Google Scholar 

  92. Zulian F et al (2010) Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 62(6):821–825

    Article  CAS  Google Scholar 

  93. Angeles-Han S, Flynn T, Lehman T (2008) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis—a case report. J Rheumatol 35(9):1897–1898

    PubMed  Google Scholar 

  94. Elhai M, Deslandre CJ, Kahan A (2011) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article By Zulian et al. Arthritis Care Res 63(2):307–308, author reply 308

    Article  Google Scholar 

  95. Parikh JG, Tawansy KA, Rao NA (2008) Immunohistochemical study of chronic nongranulomatous anterior uveitis in juvenile idiopathic arthritis. Ophthalmology 115(10):1833–1836

    Article  PubMed  Google Scholar 

  96. Heiligenhaus A et al (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 50(8):1390–1394

    Article  CAS  Google Scholar 

  97. Tappeiner C et al (2007) Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 39(3):184–186

    Article  CAS  PubMed  Google Scholar 

  98. Yuksel E et al (2014) Comparison of acute effect of systemic versus intravitreal infliximab treatment in an experimental model of endotoxin-induced uveitis. J Ocul Pharmacol Ther 30(1):74–80

    Article  CAS  PubMed  Google Scholar 

  99. Markomichelakis N et al (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet disease: a pilot study in 15 patients. Am J Ophthalmol 154(3):534–541, e1

    Article  CAS  PubMed  Google Scholar 

  100. Hosseini H et al (2009) Intravitreal infliximab in experimental endotoxin-induced uveitis. Eur J Ophthalmol 19(5):818–823

    PubMed  Google Scholar 

  101. Farvardin M, Afarid M, Shahrzad S (2012) Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther 28(6):628–631

    CAS  PubMed  Google Scholar 

  102. Farvardin M et al (2010) Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 30(9):1530–1535

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital for Special Surgery, 535 East 70th Street, New York, NY, 10021, USA

    Sergio Schwartzman

  2. Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Monica Schwartzman

Authors
  1. Sergio Schwartzman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica Schwartzman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sergio Schwartzman.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schwartzman, S., Schwartzman, M. The Use of Biologic Therapies in Uveitis. Clinic Rev Allerg Immunol 49, 307–316 (2015). https://doi.org/10.1007/s12016-014-8455-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-014-8455-6

Keywords

Search

Navigation